Nanoparticles, oral delivery, Vaccine carriers, Biodegradable polymer, PLGA, Adjuvant.
Objectives: To determine the prevalence of proton pump inhibitor use among the junior doctors in a tertiary health care centre of Manipur and to assess the practice of proton pump inhibitor use among them. Materials and Methodology: A cross-sectional study was conducted among the junior doctors i.e. internees, house officers and post graduate students in a tertiary health care centre of Manipur during November to January 2012. Respondents were purposively selected and data were collected using structured interview schedule which consists of socio-demographic variables, questions on use of PPI. Those who refused to participate and who could not be contacted even after 3 successive visits were excluded from the study. Data were analysed using SPSS 20 and was presented in mean, percentages etc. Results: Prevalence of PPI use was 66.6%. All the doctors used PPI only on selective patients. Majority of them use for gastrointestinal diseases (84%). Little more than 9 in 10 participants used PPI for the patients aged 20-30 years. Majority of them used PPI for 2-4 wks in Acid Peptic Disorder (30.5%) and less than 1week in Non Acid Peptic Disorder. More than 8 in 10 participants told that PPI was the best drug for acid peptic disorder and majority opined that PPI should not be used randomly for all gastro-intestinal disorder. Conclusion: Inappropriate use of PPI remains rampant in hospital practice. Increased awareness should be created among the clinicians so that appropriate prescription of PPIs could improve the patient care.
. National Institute for Health and Clinical Excellence. Guidance on the use of PPI in the treatment of dyspepsia. London: NICE, 2000.
. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Safety 2006;
. Hetzel D. Acid pump inhibitors. The treatment of gastroesophageal reflux. Australian Family Physician 1998; 27(6): 487-91.
. H Muhammad, Yasin F, Gardezi KM S, Adeeb F, Walker F. Inappropriate use of proton pump inhibitors among medical inpatients: a questionnaire-based observational study. J R Soc Med Sh Rep 2013; 4:36.
. Sandozi T. A Comparative Study of Cost Analysis of H2 Antagonists and Proton Pump Inhibitors in a Tertiary Care Hospital. Research Journal of Pharmaceutical, Biological and Chemical Sciences 2013; 4(1): 888-97.
. Mat Saad AZ, Collins N, Lobo MM, O Connor HJ. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59(1): 31-4.
. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001; 23(3): 116-7.
. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000; 25(5): 333-40.
. Mayet AY. Improper use of antisecretory drugs in tertiary care teaching hospital: An observational study. The Saudi Journal of
Gastroenterology 2007; 13(3):124-8.
. Bateman DN. Proton pump inhibitors: Three of a kind? Lancet 1997; 349:1637-8.
. Sebastian SS, Kernan N, Qasim A, O Morain CA, Buckley M. Appropriateness of gastric antisecretory therapy in hospital practice. Indian J Med Sci 2004; 172:115-7.
. Harris AW, Beveridge IG, Dove-Edwin I. Audit of use of antisecretory drugs. Gut 1997; 40:A59.
. Jones MI, Greenfield SM, Jowet S, Bradley CP, Seal R. Proton pump inhibitors: A study of GPs prescribing. Fam Pract 2001; 18:333-8.
. Mayet AY. Improper Use of Antisecretory Drugs in a Tertiary Care Teaching Hospital: An Observational Study. The Saudi Journal of Gastroenterology 2007; 13(3):124-8.
. Ramirez E, Lei S, Borobia A, Pinana E, Fudio S, Munoz R, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Current Clinical Pharmacology 2010; 5(4): 288-97.
. Nousheen, Tadvi NA, Shareef SM. Use of proton pump inhibitors in general practice: is it rationale? Int J Med Res Health Sci 2014; 3(1): 37-42.
How to Cite
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Author must Submit Copyright form After acceptance of Article